Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Folate Receptor α-Targeted 89Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer.

Heo GS, Detering L, Luehmann HP, Primeau T, Lee YS, Laforest R, Li S, Stec J, Lim KH, Lockhart AC, Liu Y.

Mol Pharm. 2019 Sep 3;16(9):3996-4006. doi: 10.1021/acs.molpharmaceut.9b00653. Epub 2019 Aug 16.

PMID:
31369274
2.

Complex Case of Open Fracture-Dislocation of the Elbow.

Primeau T, Beauchamp-Chalifour P, Pelet S.

Case Rep Orthop. 2019 May 13;2019:3495742. doi: 10.1155/2019/3495742. eCollection 2019.

3.

Regulated Phosphosignaling Associated with Breast Cancer Subtypes and Druggability.

Huang KL, Wu Y, Primeau T, Wang YT, Gao Y, McMichael JF, Scott AD, Cao S, Wendl MC, Johnson KJ, Ruggles K, Held J, Payne SH, Davies S, Dar A, Kinsinger CR, Mesri M, Rodriguez H, Ellis MJ, Townsend RR, Chen F, Fenyö D, Li S, Liu T, Carr SA, Ding L.

Mol Cell Proteomics. 2019 Aug;18(8):1630-1650. doi: 10.1074/mcp.RA118.001243. Epub 2019 Jun 13.

PMID:
31196969
4.

Assessment of Copper Nanoclusters for Accurate in Vivo Tumor Imaging and Potential for Translation.

Heo GS, Zhao Y, Sultan D, Zhang X, Detering L, Luehmann HP, Zhang X, Li R, Choksi A, Sharp S, Levingston S, Primeau T, Reichert DE, Sun G, Razani B, Li S, Weilbaecher KN, Dehdashti F, Wooley KL, Liu Y.

ACS Appl Mater Interfaces. 2019 Jun 5;11(22):19669-19678. doi: 10.1021/acsami.8b22752. Epub 2019 May 22.

PMID:
31074257
5.

Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer.

Liu S, Li S, Wang B, Liu W, Gagea M, Chen H, Sohn J, Parinyanitikul N, Primeau T, Do KA, Vande Woude GF, Mendelsohn J, Ueno NT, Mills GB, Tripathy D, Gonzalez-Angulo AM.

Mol Cancer Ther. 2019 Feb;18(2):399-412. doi: 10.1158/1535-7163.MCT-18-0710. Epub 2018 Dec 5.

PMID:
30518672
6.

Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.

Mundt F, Rajput S, Li S, Ruggles KV, Mooradian AD, Mertins P, Gillette MA, Krug K, Guo Z, Hoog J, Erdmann-Gilmore P, Primeau T, Huang S, Edwards DP, Wang X, Wang X, Kawaler E, Mani DR, Clauser KR, Gao F, Luo J, Davies SR, Johnson GL, Huang KL, Yoon CJ, Ding L, Fenyö D, Ellis MJ, Townsend RR, Held JM, Carr SA, Ma CX.

Cancer Res. 2018 May 15;78(10):2732-2746. doi: 10.1158/0008-5472.CAN-17-1990. Epub 2018 Feb 22.

7.

Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity.

Zhang X, Kim S, Hundal J, Herndon JM, Li S, Petti AA, Soysal SD, Li L, McLellan MD, Hoog J, Primeau T, Myers N, Vickery TL, Sturmoski M, Hagemann IS, Miller CA, Ellis MJ, Mardis ER, Hansen T, Fleming TP, Goedegebuure SP, Gillanders WE.

Cancer Immunol Res. 2017 Jul;5(7):516-523. doi: 10.1158/2326-6066.CIR-16-0264. Epub 2017 Jun 15.

8.

Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.

Wardell SE, Ellis MJ, Alley HM, Eisele K, VanArsdale T, Dann SG, Arndt KT, Primeau T, Griffin E, Shao J, Crowder R, Lai JP, Norris JD, McDonnell DP, Li S.

Clin Cancer Res. 2015 Nov 15;21(22):5121-5130. doi: 10.1158/1078-0432.CCR-15-0360. Epub 2015 May 19.

9.

A single peptide-MHC complex positively selects a diverse and specific CD8 T cell repertoire.

Wang B, Primeau TM, Myers N, Rohrs HW, Gross ML, Lybarger L, Hansen TH, Connolly JM.

Science. 2009 Nov 6;326(5954):871-4. doi: 10.1126/science.1177627.

10.

Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig.

Ponder KP, Wang B, Wang P, Ma X, Herati R, Wang B, Cullen K, O'Donnell P, Ellinwood NM, Traas A, Primeau TM, Haskins ME.

Mol Ther. 2006 Jul;14(1):5-13. Epub 2006 May 12.

11.

Applications of major histocompatibility complex class I molecules expressed as single chains.

Primeau T, Myers NB, Yu YY, Lybarger L, Wang X, Truscott SM, Hansen TH, Connolly JM.

Immunol Res. 2005;32(1-3):109-21. Review.

PMID:
16106063
12.

Enhanced immune presentation of a single-chain major histocompatibility complex class I molecule engineered to optimize linkage of a C-terminally extended peptide.

Lybarger L, Yu YY, Miley MJ, Fremont DH, Myers N, Primeau T, Truscott SM, Connolly JM, Hansen TH.

J Biol Chem. 2003 Jul 18;278(29):27105-11. Epub 2003 May 5.

Supplemental Content

Loading ...
Support Center